Barclays
RLMD icon

Barclays’s Relmada Therapeutics RLMD Stock Holding History

Barclays’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$619K Buy
88,953
+28,953
+48% +$137K ﹤0.01% 3059
2025
Q4 		$290K Buy
60,000
+50,000
+500% +$168K ﹤0.01% 4141
2025
Q3 		$20.1K Buy
10,000
+9,999
+999,900% +$9.59K ﹤0.01% 4931
2025
Q2 		$1 Buy
+1
New +$1 ﹤0.01% 5202
2025
Q1 		– Sell
-145,999
Closed -$75.9K – 5512
2024
Q4 		$75.9K Hold
145,999
– – ﹤0.01% 4652
2024
Q3 		$473K Hold
145,999
– – ﹤0.01% 3815
2024
Q2 		$438K Hold
145,999
– – ﹤0.01% 3118
2024
Q1 		$679K Hold
145,999
– – ﹤0.01% 3396
2023
Q4 		$604K Hold
145,999
– – ﹤0.01% 3767
2023
Q3 		$438K Hold
145,999
– – ﹤0.01% 2876
2023
Q2 		$359K Buy
145,999
+131,161
+884% +$363K ﹤0.01% 2945
2023
Q1 		$33.5K Buy
14,838
+5,411
+57% +$18.7K ﹤0.01% 4539
2022
Q4 		$32.9K Buy
9,427
+2,326
+33% +$20.4K ﹤0.01% 4691
2022
Q3 		$263K Sell
7,101
-9,598
-57% -$266K ﹤0.01% 3059
2022
Q2 		$317K Buy
16,699
+14,999
+882% +$327K ﹤0.01% 3161
2022
Q1 		$46K Buy
+1,700
New +$35.2K ﹤0.01% 4150

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Barclays's RLMD Position: Q1 2026 in Review

Barclays increased its Relmada Therapeutics (RLMD) stake by 48% in Q1 2026, buying an estimated $137K and bringing the position to 88,953 shares worth $619K. The position accounts for ﹤0.01% of the portfolio, ranked #3059.

Barclays first reported a position in RLMD in Q1 2022 and has held it in 16 quarters since. The position peaked at $679K in Q1 2024. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Barclays held 88,953 shares of Relmada Therapeutics worth $619K as of Q1 2026.
  • Barclays bought 28,953 Relmada Therapeutics shares in Q1 2026, an estimated $137K.
  • Relmada Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3059 holding.
  • Barclays first reported a position in Relmada Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • Barclays's Relmada Therapeutics position peaked at $679K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.